Here we go again.
Just weeks after global economies reopened, “second wave” coronavirus fears could send us all back indoors. In fact, former FDA chief Dr. Scott Gottlieb, coronavirus hot spots “could quickly get out of control.”
Already, new cases and hospitalizations are aggressively sweeping across Florida, California, Texas, Alaska, Arkansas, Kentucky, Mississippi, North Carolina, Oregon, and South Carolina. Worse, the virus continues to infect about 20,000 people a day, says Gottlieb.
If we see even more cases, it could force the economy to close up shop again.
If that’s the case, coronavirus stocks could be thrust back into the spotlight.
Alpha Pro Tech (APT)
With fears of another round of the virus, we’re likely to see a pickup in face mask demand.
Lloyd Hoffman, President and CEO of Alpha Pro Tech, commented, “The unprecedented surge in demand for our personal protective equipment, otherwise known as PPE, resulting from the outbreak of the coronavirus, COVID-19, particularly our N-95 Particulate Respirator face mask and face shields, drove quarterly sales and significantly higher gross profit for the first quarter.”
Growth shouldn’t be a problem for APT, near-term with a resurgence.
Teladoc Health (TDOC)
Of course, we could see even more demand for telehealth services.
All with hospitals, federal, and state governments around the world supporting telehealth programs to cut back on in-person meetings in in-patient and out-patient care settings. Also, according to McKinsey & Co., 76% of consumers say they were now moderately or highly interested in using telehealth, as compared to 11% in 2019.
Moderna Inc. (MRNA)
Moderna Inc. (MRNA) just advanced late-stage development of its vaccine. Better, it just finalized the Phase 3 study protocol based on feedback from US FDA.
The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants enrolled in the U.S. and is expected to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Plus, Moderna has completed manufacture of vaccine required to start the Phase 3 study, and expects dosing in the Phase 3 study to begin in July.